Use of prokinetics in the preterm infant

Current Opinion in Pediatrics

Volumn 23, Issue 2, 2011, Pages 156-160

  Lam, Hugh S ^a   Ng, Pak C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

erythromycin; gastrointestinal dysmotility; prematurity; prokinetics

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; PROKINETIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CHRONIC LUNG DISEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; ENTERIC FEEDING; GASTROINTESTINAL MOTILITY DISORDER; HEART ARRHYTHMIA; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; INTESTINE FLORA; LOW DRUG DOSE; MICROFLORA; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MACROLIDES;

EID: 79953847851     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283431f2a     Document Type: Review

References (46)

1. Neu J. Gastrointestinal maturation and implications for infant feeding. Early Hum Dev 2007; 83:767-775. (Pubitemid 350017864)
2. Craig JS. Cisapride and intestinal dysmotility: the final word? Biol Neonate 2005; 88:276-277.
3. Berseth CL. Gastrointestinal motility in the neonate. Clin Perinatol 1996; 23:179-190. (Pubitemid 26181084)
4. Lam HS, Wong SP, Cheung HM, et al. Early diagnosis of intra-abdominal inflammation and sepsis by neutrophil CD64 expression in newborns. Neonatology 2010; 99:118-124.
5. Ng PC, Ang IL, Chiu RW, et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest 2010; 120:2989-3000.
6. Lam HS, So KW, Ng PC. Osteopenia in neonates: a review. HK J Paediatr 2007; 12:118-124. (Pubitemid 46663409)
7. Cheung HM, Lam HS, Tam YH, et al. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin Nutr 2009; 28:209-212.
8. Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678-e686.
9. Kaufman SS, Gondolesi GE, Fishbein TM. Parenteral nutrition associated liver disease. Semin Neonatol 2003; 8:375-381. (Pubitemid 37237133)
10. Kaufman SS, Pehlivanova M, Fennelly EM, et al. Predicting liver failure in parenteral nutrition-dependent short bowel syndrome of infancy. J Pediatr 2010; 156:580-585.
11. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322:1028-1031. (Pubitemid 20146660)
12. Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992; 103:72-79.
13. Ng PC, Fok TF, Lee CH, et al. Erythromycin treatment for gastrointestinal dysmotility in preterm infants. J Paediatr Child Health 1997; 33:148-150. (Pubitemid 27223802)
14. Aly H, Bdel-Hady H, Khashaba M, El-Badry N. Erythromycin and feeding intolerance in premature infants: a randomized trial. J Perinatol 2007; 27:39-43. (Pubitemid 44971051)
15. ElHennawy AA, Sparks JW, Armentrout D, et al. Erythromycin fails to improve feeding outcome in feeding-intolerant preterm infants. J Pediatr Gastroenterol Nutr 2003; 37:281-286. (Pubitemid 39274518)
16. Ng PC, So KW, Fung KS, et al. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001; 84:F177-F182. (Pubitemid 32411256)
17. Ng PC, Lee CH, Wong SP, et al. High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants. Gastroenterology 2007; 132:1726-1739. (Pubitemid 46677952)
18. Ng SC, Gomez JM, Rajadurai VS, et al. Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. J Pediatr Gastroenterol Nutr 2003; 37:554-558. (Pubitemid 39280860)
19. Nuntnarumit P, Kiatchoosakun P, Tantiprapa W, Boonkasidecha S. Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants. J Pediatr 2006; 148:600-605. (Pubitemid 43776898)
20. Oei J, Lui K. A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants. Acta Paediatr 2001; 90:904-908. (Pubitemid 32762838)
21. Patole SK, Almonte R, Kadalraja R, et al. Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates? Int J Clin Pract 2000; 54:504-508.
22. Stenson BJ, Middlemist L, Lyon AJ. Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 1998; 79:F212-F214. (Pubitemid 28500680)
23. Madani A, Pishva N, Pourarian SH, Zarkesh M. The efficacy of oral erythromycin in enhancement of milk tolerance in premature infants: a randomized clinical trial. Iran J Med Sci 2004; 29:1-4. (Pubitemid 39421905)
24. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009; 155:18-23. A review article that clearly explains the development of motilin receptor agonists and the potential the newer agents have in clinical practice.
25. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998; 43:395-400. (Pubitemid 28414922)
26. Jadcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr 2002; 34:16-22. (Pubitemid 34251695)
27. Mathis C, Malbert CH. Changes in pyloric resistance induced by erythromycin. Neurogastroenterol Motil 1998; 10:131-138.
28. Bruley des Varannes S, Parys V, Ropert A, et al. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995; 109:32-39.
29. Fraser R, Shearer T, Fuller J, et al. Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric, and duodenal motility. Gastroenterology 1992; 103:114-119.
30. Holle GE, Steinbach E, Forth W. Effects of erythromycin in the dog upper gastrointestinal tract. Am J Physiol 1992; 263:G52-G59.
31. Parkman HP, Pagano AP, Vozzelli MA, Ryan JP. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Physiol 1995; 269:G418-G426.
32. Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992; 102:823-828.
33. Costalos C, Gounaris A, Varhalama E, et al. Erythromycin as a prokinetic agent in preterm infants. J Pediatr Gastroenterol Nutr 2002; 34:23-25. (Pubitemid 34251696)
34. Berseth CL. Neonatal small intestinal motility: motor responses to feeding in term and preterm infants. J Pediatr 1990; 117:777-782. (Pubitemid 20382617)
35. Bisset WM, Watt JB, Rivers RP, Milla PJ. Ontogeny of fasting small intestinal motor activity in the human infant. Gut 1988; 29:483-488.
36. Tomomasa T, Miyazaki M, Koizumi T, Kuroume T. Erythromycin increases gastric antral motility in human premature infants. Biol Neonate 1993; 63:349-352. (Pubitemid 23226427)
37. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 2007; 26:1121-1130. (Pubitemid 47480960)
38. Sorensen HT, Skriver MV, Pedersen L, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003; 35:104-106. (Pubitemid 36401435)
39. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089-1096.
40. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003:CD003744.
41. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010; 55:675-683. An interesting study which proposes that azithromycin may be as clinically effective as erythromycin, but with a better safety profile.
42. Ozaki K, Yogo K, Sudo H, et al. Effects of mitemcinal (GM-611), an acid-resistant nonpeptide motilin receptor agonist, on the gastrointestinal contractile activity in conscious dogs. Pharmacology 2007; 79:223-235. (Pubitemid 46848542)
43. Poitras P, Tomasetto C. The potential of ghrelin as a prokinetic. Regul Pept 2009; 155:24-27. A good review of a potentially important area of research in the development of prokinetic agents without antimicrobial activity.
44. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A, et al. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999; 29:33-40. (Pubitemid 29084246)
45. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002; 282:G948-G952. (Pubitemid 34651600)
46. Verhagen MA, Samsom M, Maes B, et al. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997; 11:1077-1086. (Pubitemid 27525099)